The new House democrats medicare negotiations bill represents a turning point, with broad support for using robust compulsory licensing authority to protect access if negotiations on prices break down. The press conference announcing the bill featured several Democratic members of… Continue Reading
On July 18, 2018, the U.S. House Energy and Commerce committee gave its approval to HR 6378, the Pandemic and All-Hazards Preparedness Act, known as PAHPA. During the mark up, Reps. John Shimkus (R-IL) and Tony Cárdenas (D-CA) proposed attaching… Continue Reading
The following are comments by the KEI on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, in response to notice in the Federal Register, 83 FR 22692. Overall, the Blueprint is very weak, and won’t do much… Continue Reading
Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics… Continue Reading
At around 16h35 on Thursday, 12 July 2018, the WIPO Secretariat distributed the final text of the future work program of the Standing Committee on the Law of Patents (SCP). The final text can be found here: http://www.wipo.int/edocs/mdocs/scp/en/scp_28/scp_28_11.pdf The new… Continue Reading
Geneva 15h56 On Thursday, 12 July 2018, at the 28th session of the Standing Committee on the Law of Patents (SCP) countries are negotiating over the mandate of WIPO’s future work program on a suite of issues including: 1) Exceptions… Continue Reading
On 11 July 2018, Knowledge Ecology International delivered the following statement on patents and health at the 28th session of WIPO’s Standing Committee on the Law of Patents (SCP). Statement of Knowledge Ecology International Agenda item 7 – Patents and… Continue Reading
(Update: The NIH provided a response to our comments on August 1, 2020) July 10, 2018 Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager National Center for Advancing Translational Sciences National Institutes of Health Email sury.vepa@nih.gov Re: Prospective Grant… Continue Reading
UPDATE: On July 13, 2018, KEI received a response to our comments on the prospective license to be given to ERYTHRYx Therapeutics. The brief response simply stated that NIH had already assessed the company to meet their technical and financial… Continue Reading
On July 9, 2018, KEI asked the NIH to extend the deadline for comments described on the Federal Register notice 83 FR 30448 until information about the enrollment and costs of NIH-funded clinical trials involving mesothelin expressing cancers, and trials… Continue Reading